Search

Displaying results 1611 - 1620 of 8195 in total
  1. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  2. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an

  3. Drug

    PF-03758309

    go.drugbank.com/drugs/DB11775
    Investigational

    PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.

    Salts: Pf 03758309 Hydrochloride
  4. Drug

    Loxapine

    go.drugbank.com/drugs/DB00408
    ApprovedInvestigational

    An antipsychotic agent used in schizophrenia. [PubChem]

    Categories: P-glycoprotein inhibitors, Dopamine D2 Receptor Antagonists
  5. Drug

    PF-477736

    go.drugbank.com/drugs/DB12611
    Investigational

    PF-00477736 has been used in trials studying the treatment of Neoplasms.

  6. Drug

    PF-04217903

    go.drugbank.com/drugs/DB12848
    Investigational

    PF-04217903 has been used in trials studying the treatment of Neoplasms.

  7. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. Thrombin Alfa is identical in amino acid sequence and structurally similar to naturally occurring human throm...

  8. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    [A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by … [A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  9. Drug

    Cetuximab

    go.drugbank.com/drugs/DB00002
    ApprovedInvestigational

    Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the...

  10. Drug

    Isosorbide

    go.drugbank.com/drugs/DB09401
    ApprovedInvestigational

    Isosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued. … Currently, isosorbide is an organic nitrate currently available in the [isosorbide mononitrate] and [isosorbide dinitrate] forms, and is used for the prevention of angina.